KAUST researchers developed a statistical approach to improve the identification of cancer-related protein mutations by reducing false positives. The method uses Bayesian statistics to analyze protein domain data from tumor samples, accounting for potential errors due to limited data. The team tested their method on prostate cancer data, successfully identifying a known cancer-linked mutation in the DNA binding protein cd00083. Why it matters: This enhances the reliability of cancer research at the molecular level, potentially accelerating the discovery of new therapeutic targets.
Natasa Przulj at the Barcelona Supercomputing Center is developing an AI framework that fuses multi-omic data to improve precision medicine. The framework uses graph-regularized non-negative matrix tri-factorization (NMTF) and network science algorithms for patient stratification, biomarker prediction, and drug repurposing. It is applied to diseases like cancer, Covid-19, and Parkinson's. Why it matters: This research can enable more personalized and effective treatments by leveraging complex biological data to understand disease mechanisms and tailor therapies.
KAUST's Sciencetown podcast episode 23 features researcher Dana Al-Sulaiman discussing portable biosensing technologies for cancer detection. These devices aim to enable liquid biopsies for early screening and personalized treatment. The biosensors gather clinical information from biological samples to inform clinical decisions. Why it matters: This research can advance non-invasive diagnostics and personalized medicine in the region.
MBZUAI researchers are refining AI techniques to improve cancer diagnosis for colorectal and breast cancer, both common in the Middle East. They are using "few-shot tissue image generation," in which AI generates data for training AI models to recognize lesions, addressing the challenge of limited training data. The developed framework improves the efficiency of radiologists in breast cancer diagnosis, leading to better detection of breast lesions and timely treatment interventions. Why it matters: These advancements in AI-aided diagnostics can lead to earlier and more accurate cancer detection, ultimately improving patient outcomes in the region and beyond.
A senior lecturer at the University of New South Wales discussed the use of AI to improve early prognosis and personalized treatment plans for neurodegenerative diseases, cardiovascular imaging and multiomics. The lecture highlighted the potential of AI algorithms to detect subtle changes at early stages through advanced multiomics techniques and medical imaging analysis. The speaker has expertise in analyzing medical images and has collaborated with medical professionals to develop AI tools for diagnosis of cancer, neurodegenerative disease, and heart disease. Why it matters: AI-driven prognosis and treatment planning promises earlier intervention and improved outcomes for challenging diseases in the region.
Pierre Baldi from UC Irvine presented applications of AI to biomedicine, covering molecular-level analysis of circadian rhythms, real-time polyp detection in colonoscopy videos, and prediction of post-operative adverse outcomes. He discussed integrating AI in future AI-driven hospitals. The presentation was likely part of a panel discussion hosted by MBZUAI in collaboration with the Manara Center for Coexistence and Dialogue. Why it matters: This highlights the growing interest in AI applications within the healthcare sector in the UAE, particularly through institutions like MBZUAI.
Eran Segal from Weizmann Institute of Science presented The Human Phenotype Project, a large-scale prospective cohort with over 10,000 participants. The project aims to identify novel molecular markers and develop prediction models for disease onset using deep profiling. The profiling includes medical history, lifestyle, blood tests, and molecular profiling of the transcriptome, genetics, microbiome, metabolome and immune system. Why it matters: Such projects demonstrate the growing focus on personalized medicine in the region, utilizing advanced AI and machine learning techniques for disease prevention and treatment.
KAUST and King Faisal Specialist Hospital and Research Centre (KFSH&RC) are collaborating to develop bioelectronic sensors for rapid pathogen detection. These sensors aim to provide cheap and accurate results, potentially replacing conventional lab tests. A COVID-19 saliva test developed by KAUST researchers showed comparable sensitivity to PCR tests with a 15-minute turnaround. Why it matters: This partnership accelerates the development of novel diagnostic tools, which could improve healthcare accessibility in remote areas and low-income countries within the region.